行情

AGIO

AGIO

Agios制药
NASDAQ

实时行情|Nasdaq Last Sale

36.88
+0.30
+0.82%
交易中 10:07 09/18 EDT
开盘
36.72
昨收
36.58
最高
37.19
最低
36.24
成交量
2.64万
成交额
--
52周最高
79.17
52周最低
33.17
市值
21.67亿
市盈率(TTM)
-5.5277
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGIO 新闻

  • IMF首席经济学家:全球经济前景受限 需要财政支持
  • 新浪美股.1分钟前
  • 美国总统特朗普宣布加大对伊朗制裁
  • 央视.18分钟前
  • 开盘:等待联储决议 美股周三低开
  • 新浪美股.36分钟前
  • 美联储决议终极前瞻:年内第二次降息无悬念
  • 汇通网.46分钟前

更多

所属板块

生物技术和医学研究
-0.77%
制药与医学研究
-0.31%

热门股票

名称
价格
涨跌幅

AGIO 简况

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
展开

Webull提供Agios Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。